Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2010121238) METHODS AND KITS TO PREDICT THERAPEUTIC OUTCOME OF TYROSINE KINASE INHIBITORS
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2010/121238 International Application No.: PCT/US2010/031558
Publication Date: 21.10.2010 International Filing Date: 19.04.2010
IPC:
C12P 21/06 (2006.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
P
FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
21
Preparation of peptides or proteins
06
produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
Applicants:
WEISS, Glen [US/US]; US
TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN) [US/US]; Translational Genomics Research Institute 445 N. 5th St. Suite 600 Phoenix, Arizona 85004, US (AllExceptUS)
Inventors:
WEISS, Glen; US
Agent:
JACKSON, Jeffrey; Translational Genomics Research Institute 445 N. 5th St. Suite 600 Phoenix, Arizona 85004, US
Priority Data:
61/170,26017.04.2009US
61/293,68510.01.2010US
Title (EN) METHODS AND KITS TO PREDICT THERAPEUTIC OUTCOME OF TYROSINE KINASE INHIBITORS
(FR) MÉTHODES ET KITS PERMETTANT DE PRÉDIRE LE RÉSULTAT THÉRAPEUTIQUE D'INHIBITEURS DE LA TYROSINE KINASE
Abstract:
(EN) Methods of using specific microRNA to identify subjects with non-small cell lung cancer likely or unlikely to respond to treatment with tyrosine kinase inhibitors such as erlotinib, sunitinib, or vandetanib; methods of treating subjects based on identification of said subjects as likely to respond to treatment with tyrosine kinase inhibitors; and kits that facilitate the performance of the methods are disclosed.
(FR) La présente invention concerne des méthodes d'utilisation de microARN spécifique permettant d'identifier des sujets atteints de cancer des poumons à grandes cellules comme étant susceptibles ou non de réagir à un traitement utilisant des inhibiteurs de la tyrosine kinase, tels qu'erlotinibe, sunitinibe ou vandetanibe. L'invention porte en outre sur des méthodes de traitement de sujets sur la base de l'identification desdits sujets comme étant susceptibles de réagir à un traitement utilisant des inhibiteurs de la tyrosine kinase. L'invention concerne également des kits qui facilitent la réalisation desdites méthodes.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)